Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Insulet reports before market open, meaning Day 0 represents the first trading session where the market reacts to results, while Day +1 captures follow-through momentum.

Historical price behavior shows significant volatility around earnings, with the stock averaging 6.71% absolute movement on Day 0 and 6.06% on Day +1. The Day 0 range averages 8.02%, indicating substantial intraday volatility as investors digest results.

The direction of moves has been mixed but recently volatile. The most recent August 2026 earnings triggered a sharp 20.12% decline on Day 0, the largest single-day move in the dataset, followed by a 4.53% recovery on Day +1. Prior to that, May 2026 saw a 9.70% Day 0 decline but a strong 6.03% Day +1 bounce. Earlier reports in February and November 2025 produced more modest initial reactions but demonstrated the stock's tendency for significant follow-through moves.

The historical pattern suggests investors should prepare for substantial price movement, with recent quarters showing particular sensitivity to competitive dynamics and forward guidance. The wide Day 0 ranges indicate that initial market reactions can be volatile before settling into a clearer trend on Day +1.

Part 2.2: Options Market Expected Move

The options market is pricing an 11.09% expected move by November 20 expiration, significantly higher than the 6.71% average Day 0 move and 6.06% average Day +1 move from recent earnings history. This elevated implied volatility suggests options traders are anticipating above-average price movement, likely reflecting heightened uncertainty around competitive dynamics and type 2 diabetes adoption trends.

Part 3: What Analysts Are Saying

Analysts maintain a Buy consensus on Insulet with an average rating of 4.04 and a mean price target of $166.08, implying 7.2% upside from the current price of $154.86. The rating breakdown shows 13 Strong Buys, 2 Moderate Buys, and 12 Holds, with no sell ratings among the 27 analysts covering the stock.

Price target estimates range from a low of $144.00 to a high of $205.00, reflecting divergent views on how successfully the company can navigate competitive pressures while expanding into type 2 diabetes. The wide range suggests meaningful uncertainty about the medium-term trajectory.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 4.08 to 4.04 and the number of Hold ratings increasing from 11 to 12. This modest downgrade reflects growing caution about near-term competitive dynamics, though the overall stance remains constructive. The absence of any sell ratings indicates analysts still view the long-term opportunity favorably despite tactical headwinds.

The consensus price target of $166.08 sits well below the stock's 52-week high of $354.88, suggesting analysts have significantly reset expectations following the competitive pressure that emerged earlier in 2026. The current target implies modest upside, positioning the stock as a show-me story where execution against type 2 expansion goals will be critical to rekindling more bullish sentiment.

Part 4: Technical Picture

The Barchart Technical Opinion shows a 24% Sell signal, representing a significant improvement from 40% Sell last week and 100% Sell last month, indicating technical conditions have been steadily recovering from oversold levels.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests near-term momentum has stabilized after recent weakness
• Medium-term (50% Sell): Moderate sell signal indicates the intermediate trend remains under pressure
• Long-term (50% Sell): Moderate sell signal reflects continued weakness in the longer-term trend structure

Trend Characteristics: The signal strength is at minimum levels with a weakening direction, suggesting the technical environment remains fragile heading into earnings despite recent stabilization.

The stock is trading at $154.86, positioned above its 5-day ($151.92), 10-day ($149.77), 20-day ($143.91), 50-day ($141.21), and 100-day ($147.79) moving averages, indicating improving short-term momentum. However, the price remains below the 200-day moving average of $177.47, confirming the longer-term downtrend remains intact.

The technical setup heading into earnings is mixed, with short-term momentum improving but longer-term damage still evident. The stock has built a cushion above all shorter-term moving averages, suggesting some technical support has formed after the sharp decline from the $354.88 high. However, the 200-day moving average at $177.47 represents significant overhead resistance, and the stock would need to reclaim that level to signal a meaningful trend reversal. The recovering but still-weak technical opinion signals suggest the setup is cautiously supportive for a positive earnings reaction, but any disappointment could quickly reverse recent gains given the fragile trend structure.